FDA Approves Sorilux for Adolescent Plaque Psoriasis
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
A study found increases in collagen, elastin, and other extracellular matrix proteins following Radiesse treatment, along with improvements in markers of solar elastosis, a sign of sun-damaged skin.